$530 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 74 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 62.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IWM | Sell | ISHARES TRput | $38,115,000 | -44.7% | 250,000 | -46.2% | 7.20% | -41.7% |
| XBI | Sell | SPDR SERIES TRUSTput | $29,705,000 | -38.7% | 350,000 | -37.5% | 5.61% | -35.5% |
| EDGE | Sell | EDGE THERAPEUTICS INC | $8,844,000 | -34.2% | 943,906 | -24.7% | 1.67% | -30.7% |
| EVH | Sell | EVOLENT HEALTH INCcl a | $5,166,000 | -35.5% | 420,000 | -6.7% | 0.98% | -32.1% |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS | $4,419,000 | -15.4% | 900,000 | -9.7% | 0.83% | -10.9% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $2,710,000 | -57.7% | 90,000 | -47.1% | 0.51% | -55.4% |
| VIVE | Sell | VIVEVE MED INC | $2,154,000 | -50.3% | 433,419 | -47.6% | 0.41% | -47.6% |
| SGEN | Sell | SEATTLE GENETICS INCput | $1,605,000 | -57.9% | 30,000 | -57.1% | 0.30% | -55.6% |
| NVTA | Sell | INVITAE CORP | $1,383,000 | -72.0% | 152,300 | -71.2% | 0.26% | -70.6% |
| EVTC | Sell | EVERTEC INCput | $751,000 | -31.1% | 55,000 | -20.1% | 0.14% | -27.2% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $632,000 | -86.0% | 43,900 | -85.4% | 0.12% | -85.3% |
| MDXG | Sell | MIMEDX GROUP INCput | $631,000 | -24.2% | 50,000 | -28.6% | 0.12% | -20.1% |
| MNKD | Sell | MANNKIND CORPput | $400,000 | -47.4% | 172,500 | -50.7% | 0.08% | -44.1% |
| EVH | Sell | EVOLENT HEALTH INCcall | $400,000 | -72.9% | 32,500 | -60.8% | 0.08% | -71.3% |
| LXRX | Sell | LEXICON PHARMACEUTICALS INCput | $321,000 | -34.8% | 32,500 | -18.8% | 0.06% | -30.7% |
| ONSIZ | Exit | ONCOBIOLOGICS INC*w exp 05/18/201 | $0 | – | -96,833 | -100.0% | -0.00% | – |
| ONSIW | Exit | ONCOBIOLOGICS INC*w exp 02/18/201 | $0 | – | -96,833 | -100.0% | -0.00% | – |
| OTIC | Exit | OTONOMY INCcall | $0 | – | -17,500 | -100.0% | -0.01% | – |
| AXGT | Exit | AXOVANT SCIENCES LTDcall | $0 | – | -20,300 | -100.0% | -0.02% | – |
| DBVT | Exit | DBV TECHNOLOGIES S Acall | $0 | – | -9,000 | -100.0% | -0.07% | – |
| CBMX | Exit | COMBIMATRIX CORPORATION | $0 | – | -111,912 | -100.0% | -0.15% | – |
| RARX | Exit | RA PHARMACEUTICALS INC | $0 | – | -71,500 | -100.0% | -0.19% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INCput | $0 | – | -20,000 | -100.0% | -0.19% | – |
| AXDX | Exit | ACCELERATE DIAGNOSTICS INCput | $0 | – | -60,000 | -100.0% | -0.24% | – |
| CBMXW | Exit | COMBIMATRIX CORPORATION*w exp 03/18/202 | $0 | – | -564,200 | -100.0% | -0.25% | – |
| AIMT | Exit | AIMMUNE THERAPEUTICS INC | $0 | – | -58,525 | -100.0% | -0.26% | – |
| GOGO | Exit | GOGO INCput | $0 | – | -135,000 | -100.0% | -0.29% | – |
| NITE | Exit | NIGHTSTAR THERAPEUTICS PLCadr | $0 | – | -100,000 | -100.0% | -0.34% | – |
| CNC | Exit | CENTENE CORP DELput | $0 | – | -20,000 | -100.0% | -0.35% | – |
| ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -15,000 | -100.0% | -0.38% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INCcall | $0 | – | -151,000 | -100.0% | -0.41% | – |
| LCI | Exit | LANNET INCput | $0 | – | -127,500 | -100.0% | -0.42% | – |
| QTNT | Exit | QUOTIENT LTD | $0 | – | -569,145 | -100.0% | -0.50% | – |
| TOCA | Exit | TOCAGEN INC | $0 | – | -251,112 | -100.0% | -0.56% | – |
| ZGNX | Exit | ZOGENIX INCput | $0 | – | -160,000 | -100.0% | -1.00% | – |
| JNJ | Exit | JOHNSON & JOHNSONput | $0 | – | -45,000 | -100.0% | -1.05% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INCcall | $0 | – | -80,000 | -100.0% | -1.18% | – |
| DBVT | Exit | DBV TECHNOLOGIES S Asponsored adr | $0 | – | -192,000 | -100.0% | -1.46% | – |
| DBVT | Exit | DBV TECHNOLOGIES S Aput | $0 | – | -200,000 | -100.0% | -1.52% | – |
| IMMU | Exit | IMMUNOMEDICS INCcall | $0 | – | -667,500 | -100.0% | -1.67% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.